TNF-α MEDIATED SECRETORY COMPONENT IS POSITIVELY REGULATED BY PI3K/AKT/MTOR IN CACO-2 CELLS

被引:2
|
作者
Liu, Dongyan [1 ,2 ]
Wang, Si
Jiang, Teng
Ding, Peng
机构
[1] China Med Univ, Affiliated Shengjing Hosp, Res Ctr, Shenyang 110004, Liaoning Provin, Peoples R China
[2] China Med Univ, Minist Hlth, Key Lab Congenital Malformat Res, Shenyang 110004, Liaoning Provin, Peoples R China
基金
中国国家自然科学基金;
关键词
secretory component; polymeric Ig receptor; tumour necrosis factor-alpha; phosphoinositide; 3-kinase; mammalian target of rapamycin; POLYMERIC IMMUNOGLOBULIN RECEPTOR; ENTEROTOXIGENIC ESCHERICHIA-COLI; IG RECEPTOR; EXPRESSION; BINDING; PROTEIN; TRANSCYTOSIS; LACTOFERRIN; LINE;
D O I
10.2478/jomb-2013-0008
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Secretory component (SC) is the extracellular component of the polymeric immunoglobulin receptor (pIgR) that functions as a receptor for externally secreted polymeric immunoglobulins such as secretory IgA. SC expression is regulated by a signaling pathway involving TNF-alpha. Methods: Caco-2 cells were cotreated with TNF-alpha plus either Wortmannin, which inhibits PI3K, or Rapamycin, which inhibits mTOR. The expression of SC and pIgR mRNA were assessed by immunocytochemistry, Western blotting, and Quantitative real-time PCR. Results: Wortmannin and Rapamycin decreased the fraction of cells expressing SC, as well as the total expression of SC protein and pIgR mRNA. Conclusions: TNF-alpha regulation of SC expression is mediated through a PI3K/AKT/mTOR signaling pathway in Caco-2 cells.
引用
收藏
页码:116 / 120
页数:5
相关论文
共 50 条
  • [21] miR-125a inhibits the migration and invasion of liver cancer cells via suppression of the PI3K/AKT/mTOR signaling pathway
    Tang, Hao
    Li, Rong-Ping
    Liang, Ping
    Zhou, Ya-Long
    Wang, Guang-Wei
    ONCOLOGY LETTERS, 2015, 10 (02) : 681 - 686
  • [22] ABI3, a component of the WAVE2 complex, is potentially regulated by PI3K/AKT pathway
    Moraes, Lais
    Zanchin, Nilson I. T.
    Cerutti, Janete M.
    ONCOTARGET, 2017, 8 (40) : 67769 - 67781
  • [23] The exosome-mediated PI3k/Akt/mTOR signaling pathway in cervical cancer
    Zhang, Wenyuan
    Zhou, Qing
    Wei, Yunhai
    Da, Miao
    Zhang, Chun
    Zhong, Jing
    Liu, Jin
    Shen, Junjun
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2019, 12 (07): : 2474 - 2484
  • [24] Anlotinib Inhibiting Mantle Cell Lymphoma Proliferation and Inducing Apoptosis through PI3K/AKT/mTOR Pathway
    Wang, Jiaping
    Xu, Zhijuan
    Lai, Yanli
    Zhang, Yanli
    Zhang, Ping
    Mu, Qitian
    Yang, Shujun
    Sheng, Lixia
    Ouyang, Guifang
    CURRENT MOLECULAR MEDICINE, 2024,
  • [25] Targeting PI3K/AKT/mTOR network for treatment of leukemia
    Bertacchini, Jessika
    Heidari, Nazanin
    Mediani, Laura
    Capitani, Silvano
    Shahjahani, Mohammad
    Ahmadzadeh, Ahmad
    Saki, Najmaldin
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2015, 72 (12) : 2337 - 2347
  • [26] Inhibition of the PI3K/AKT/mTOR pathway in pancreatic cancer: is it a worthwhile endeavor?
    Ouissam, Al Jarroudi
    Hind, Chibani
    Aziz, Brahmi Sami
    Said, Afqir
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [27] Nanocurcumin alleviates insulin resistance and pancreatic deficits in polycystic ovary syndrome rats: Insights on PI3K/AkT/mTOR and TNF-α modulations
    Abuelezz, Nermeen Z.
    Shabana, Marwa E.
    Abdel-Mageed, Heidi M.
    Rashed, Laila
    Morcos, George N. B.
    LIFE SCIENCES, 2020, 256
  • [28] Amlodipine inhibits TNF-α production and attenuates cardiac dysfunction induced by lipopolysaccharide involving PI3K/Akt pathway
    Li, Xiao-Qiang
    Cao, Wei
    Li, Tao
    Zeng, Ai-Guo
    Hao, Li-Li
    Zhang, Xiao-Nan
    Mei, Qi-Bing
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2009, 9 (09) : 1032 - 1041
  • [29] PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer
    Li, HaiXia
    Zeng, JianFang
    Shen, Keng
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2014, 290 (06) : 1067 - 1078
  • [30] Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC
    Heavey, Susan
    O'Byrne, Kenneth J.
    Gately, Kathy
    CANCER TREATMENT REVIEWS, 2014, 40 (03) : 445 - 456